Ancilia Biosciences develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications.
The company is developing a proprietary platform that leverages the natural function of CRISPR to produce a new class of live biotherapeutics (LBPs) with engineered immunity to viral phages. These viral phages, or bacteriophages, comprise approximately half of the gut microbiome. Ancilia says that there is evidence that they contribute to disease and potentially limit the efficacy of LBPs.
The Ancilia platform is being developed as an essential enabling technology that identifies potentially problematic viruses in the gut using a proprietary approach to viral characterization. It then leverages the natural immune function of CRISPR to produce a new class of live biotherapeutics with immunity to these viruses.
Ancilia’s scientists have demonstrated proof of principle and filed key patents for the technology. The company’s founders and advisers include scientific leaders across CRISPR and the virome, including CSO Rodolphe Barrangou, PhD, a CRISPR pioneer who is a co-founder of Intellia Therapeutics and a former chairman of Caribou Biosciences.
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies …
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness …
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built …
